BTK and lupus nephritis: BTK inhibitors (PF-06250112, M7583, BI-BTK-1, RN-486, ibrutinib, poseltinib, and evobrutinib) have demonstrated the prevention or amelioration of lupus nephritis and other SLE symptoms in mouse models of SLE [45,111,112,113].